-
公开(公告)号：US20190194216A1
公开(公告)日：2019-06-27
申请号：US16217749
申请日：2018-12-12
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yat Sun Or , Jun Ma , Guoqiang Wang , Xuechao Xing , Ruichao Shen , Bin Wang
IPC: C07D491/048 , C07D493/04 , C07D487/04 , C07D417/14
CPC classification number: C07D491/048 , C07D417/14 , C07D487/04 , C07D493/04
Abstract: The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
-
公开(公告)号：US10246439B2
公开(公告)日：2019-04-02
申请号：US15988783
申请日：2018-05-24
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Brett Granger , Guoqiang Wang , Ruichao Shen , Jun Ma , Xuechao Xing , Jing He , Yong He , Jiang Long , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D487/08 , C07D491/08 , C07D513/04 , C07D417/14
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
23.发明申请公开(公告)号：US20190062310A1
公开(公告)日：2019-02-28
申请号：US16113611
申请日：2018-08-27
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Guoqiang Wang , Jing He , Bin Wang , Ruichao Shen , Brett Granger , Yat Sun Or
IPC: C07D401/14 , C07D413/14 , C07D471/04
CPC classification number: C07D401/14 , A61P1/16 , A61P3/10 , A61P13/12 , C07D413/14 , C07D471/04
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
公开(公告)号：US20180362502A1
公开(公告)日：2018-12-20
申请号：US15988783
申请日：2018-05-24
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Brett Granger , Guoqiang Wang , Ruichao Shen , Jun Ma , Xuechao Xing , Jing He , Yong He , Jiang Long , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D417/14 , C07D513/04 , C07D491/08 , C07D487/08
CPC classification number: C07D401/14 , C07D417/14 , C07D487/08 , C07D491/08 , C07D513/04
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
公开(公告)号：US10149835B2
公开(公告)日：2018-12-11
申请号：US15597431
申请日：2017-05-17
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yat Sun Or , Xuechao Xing , Ruichao Shen , Bin Wang , Brett Granger , Jun Ma , Jing He , Jiang Long , Yong He , Guoqiang Wang
IPC: A61K31/42 , C07D225/04 , C07D213/127 , C07D261/08 , C07C317/38
Abstract: The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR and methods for their preparation and use.
-
Patent Agency Ranking
公开(公告)号：US10080743B2
公开(公告)日：2018-09-25
申请号：US15497359
申请日：2017-04-26
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yat Sun Or , Bin Wang , Xuechao Xing , Ruichao Shen , Brett Granger , Jun Ma , Jing He , Yong He , Jiang Long , Guoqiang Wang
IPC: C07D261/08 , C07D413/12 , A61K31/42 , A61K31/422
CPC classification number: A61K31/42 , A61K31/422 , C07D261/08 , C07D413/12
Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
-
公开(公告)号：US20180141941A1
公开(公告)日：2018-05-24
申请号：US15793554
申请日：2017-10-25
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Jing He , Guoqiang Wang , Ruichao Shen , Xuechao Xing , Bin Wang , Jun Ma , Yat Sun Or
CPC classification number: C07D451/02 , A61P1/00 , A61P1/16 , A61P3/00 , A61P9/00 , A61P11/00 , A61P13/12
Abstract: The present invention provides compounds of Formula I, Pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
-
公开(公告)号：US20140341851A1
公开(公告)日：2014-11-20
申请号：US14245001
申请日：2014-04-04
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： YAO-LING QIU , Ce Wang , Xiaowen Peng , Hui Cao , Lu Ying , Xuri Gao , Bin Wang , Yat Sun Or
IPC: C07D498/10 , A61K31/4184 , C07D401/14 , A61K31/444 , C07D405/14 , A61K31/4545 , A61K31/5377 , A61K31/496 , C07F9/6506 , A61K31/675 , C07D487/08 , A61K31/506 , C07D409/14 , C07D413/14 , A61K31/422 , C07D491/107 , A61K31/517 , C07D417/14 , A61K45/06 , C07D403/14
CPC classification number: C07D498/10 , A61K31/13 , A61K31/4184 , A61K31/422 , A61K31/427 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/517 , A61K31/5377 , A61K31/675 , A61K31/7056 , A61K38/19 , A61K38/21 , A61K45/06 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D487/08 , C07D491/107 , C07F9/65583 , A61K2300/00 , A61K39/12
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
-
公开(公告)号：US20230174515A1
公开(公告)日：2023-06-08
申请号：US18073728
申请日：2022-12-02
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Ruichao Shen , Jiang Long , Jun Ma , Xuechao Xing , Yong He , Brett Granger , Jing He , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D417/14 , C07D413/14 , C07D403/12 , C07D403/14 , C07D405/14
CPC classification number: C07D401/14 , C07D417/14 , C07D413/14 , C07D403/12 , C07D403/14 , C07D405/14
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof:
which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).-
公开(公告)号：US20200331890A1
公开(公告)日：2020-10-22
申请号：US16866778
申请日：2020-05-05
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Ruichao Shen , Jiang Long , Jun Ma , Xuechao Xing , Yong He , Brett Granger , Jing He , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D417/14 , C07D413/14 , C07D403/12 , C07D403/14 , C07D405/14
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
-
-
-
-
-
-
-
-
Search Results
64
records
(took 0.047 seconds)
